Sotorasib for Vascular Malformations Associated with KRAS G12C Mutation.

doi:10.1056/NEJMoa2309160

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Sotorasib for Vascular Malformations Associated with KRAS G12C Mutation.

The New England journal of medicine - 25 Jul 2024

Fraissenon Antoine, Bayard Charles, Morin Gabriel, Benichi Sandro, Hoguin Clément, Protic Sanela, Zerbib Lola, Ladraa Sophia, Firpion Marina, Blauwblomme Thomas, Naggara Olivier, Duruisseaux Michael, Delous Marion, Boitel Clothilde, Bringuier Pierre-Paul, Payen Léa, Legendre Christophe, Kaltenbach Sophie, Balducci Estelle, Villarese Patrick, Asnafi Vahid, Bisdorff Annouk, Guibaud Laurent, Canaud Guillaume

Abstract excerpt

KRAS gain-of-function mutations are frequently observed in sporadic arteriovenous malformations. The mechanisms underlying the progression of such KRAS-driven malformations are still incompletely understood, and no treatments for the condition are approved. Here, we show the effectiveness of sotorasib, a specific KRAS G12C inhibitor, in reducing the volume of vascular malformations and improving survival in two...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arteriovenous Malformations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cardiovascular Agents

Share to Disease Models, Animal

Share to Gain of Function Mutation

Share to Piperazines

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyridines

Share to Pyrimidines

Source

Open in PubMed

Identifiers

PMID: 39018528
DOI: 10.1056/NEJMoa2309160

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sotorasib for Vascular Malformations Associated with KRAS G12C Mutation.PMID 39018528Read ↗

Trametinib as a promising therapeutic option in alleviating vascular defects in an endothelial KRAS-induced mouse model.Semantic proximity Read ↗

New and Emerging Targeted Therapies for Vascular Malformations.Semantic proximity Read ↗

Molecular landscape and classification of vascular anomalies.Semantic proximity Read ↗

Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling.Semantic proximity Read ↗

Targeted treatments for vascular malformations: current state of the art.Semantic proximity Read ↗

Advances in the Study of KRAS in Brain Arteriovenous Malformation.Semantic proximity Read ↗

Targeted Therapies for Slow‐Flow Vascular MalformationsSemantic proximity Read ↗

Development of Molecular Therapies for Venous Malformations.Semantic proximity Read ↗

KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2K-MAPK1 inhibition.Semantic proximity Read ↗

How we approach the use of sirolimus and new agents: Medical therapy to treat vascular anomalies.Semantic proximity Read ↗

Targeted medical therapies for vascular anomaliesSemantic proximity Read ↗

MEK signaling represents a viable therapeutic vulnerability of <i>KRAS</i> -driven somatic brain arteriovenous malformationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.